ArticleBlood advances2026

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Marie Anne-Catherine Neumann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.